Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival
-
Published:2022-10
Issue:
Volume:65
Page:110-115
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
van der Voort AnnaORCID,
Liefaard Marte C.ORCID,
van Ramshorst Mette S.,
van Werkhoven ErikORCID,
Sanders Joyce,
Wesseling Jelle,
Scholten Astrid,
Vrancken Peeters Marie Jeanne T.F.D.,
de Munck LindaORCID,
Siesling SabineORCID,
Sonke Gabe S.ORCID
Subject
General Medicine,Surgery
Reference30 articles.
1. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial;Gianni;Lancet Oncol,2012
2. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA);Schneeweiss;Ann Oncol,2013
3. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study;Swain;Ann Oncol,2018
4. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial;van Ramshorst;Lancet Oncol,2018
5. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer;von Minckwitz;N Engl J Med,2017
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献